Logo Image

Pedro C. Barata, MD, MSc, FACP

Articles by Pedro C. Barata, MD, MSc, FACP

Postimmunotherapy Options in RCC: Latest Trial Data and Expert Perspectives on Rechallenge Strategies

ByPedro C. Barata, MD, MSc, FACP ,Moshe Ornstein, MD,Elizabeth Wulff-Burchfield, MD ,Kathryn E. Beckermann, MD, PhD

Experts discuss key findings from the phase 3 CONTACT-03 trial investigating atezolizumab plus cabozantinib vs cabozantinib alone in inoperable advanced renal cell carcinoma (aRCC) after immune checkpoint inhibitor (ICI) treatment, along with insights from real-world data on sequencing strategies and the efficacy of tyrosine kinase inhibitors (TKIs) after prior ICI therapy.

Navigating RCC Progression: Optimizing Treatment Sequence After the First Line

ByPedro C. Barata, MD, MSc, FACP ,Moshe Ornstein, MD,Elizabeth Wulff-Burchfield, MD ,Kathryn E. Beckermann, MD, PhD

Experts discuss emerging patterns of progression with current frontline regimens for advanced renal cell carcinoma (RCC), differences between immunotherapy (IO)/IO and IO/tyrosine kinase inhibitor (TKI) combinations, and how these progression patterns impact prognosis and subsequent therapy selection, considering whether the patient received IO/IO or IO/TKI in the first line and the clinical factors influencing later-line treatment decisions.

Optimizing IO/TKI Success: Managing Adverse Effects and Personalizing Treatment

ByPedro C. Barata, MD, MSc, FACP ,Moshe Ornstein, MD,Elizabeth Wulff-Burchfield, MD ,Kathryn E. Beckermann, MD, PhD

Experts discuss regimens with the most favorable toxicity profiles and how they personalize treatment to minimize patient burden, while also exploring preferred strategies for patients who have completed pembrolizumab in the adjuvant setting and how the timing of recurrence relative to adjuvant therapy completion influences treatment selection.

RCC Treatment Selection: Expert Perspectives on Long-Term Data and Insights on Treatment Selection

ByPedro C. Barata, MD, MSc, FACP ,Moshe Ornstein, MD,Elizabeth Wulff-Burchfield, MD ,Kathryn E. Beckermann, MD, PhD

Experts discuss key factors influencing the decision between immunotherapy (IO)/IO and various IO/tyrosine kinase inhibitor (TKI) combinations in advanced renal cell carcinoma (RCC) treatment, including patient characteristics, risk stratification, PD-L1 status, and other clinical features, while also exploring the patient experience with IO-TKI regimens, strategies for managing adverse effects, and the approach to hepatotoxicity management.

Long-Term Data From CheckMate 9ER Investigating Nivolumab Plus Cabozantinib in Untreated Advanced RCC

ByPedro C. Barata, MD, MSc, FACP ,Moshe Ornstein, MD,Elizabeth Wulff-Burchfield, MD ,Kathryn E. Beckermann, MD, PhD

Experts discuss the key findings from the final follow-up results of the CheckMate 9ER trial, evaluating nivolumab plus cabozantinib in advanced renal cell carcinoma (RCC) and share perspectives on the clinical implications of these updated data, along with insights from other studies of note, including LITESPARK-003 (belzutifan plus cabozantinib) and LITESPARK-024 (belzutifan plus palbociclib).

Optimizing IO-TKI Selection: Patient-Specific Approaches for Optimal Outcomes

ByPedro C. Barata, MD, MSc, FACP ,Moshe Ornstein, MD,Elizabeth Wulff-Burchfield, MD ,Kathryn E. Beckermann, MD, PhD

Experts discuss how emerging novel doublet regimens in the frontline setting for advanced renal cell carcinoma may address current unmet needs, highlighting specific biomarkers, patient populations, and clinical scenarios where these combinations could offer distinct advantages over existing standards like immunotherapy (IO)/IO or established IO/tyrosine kinase inhibitor (TKI) combinations.

Long-Term Outcomes in Advanced RCC: Analyzing 8 Years of CheckMate 214 Data

ByPedro C. Barata, MD, MSc, FACP ,Moshe Ornstein, MD,Elizabeth Wulff-Burchfield, MD ,Kathryn E. Beckermann, MD, PhD

Experts discuss the 8-year follow-up data from the CheckMate 214 trial evaluating nivolumab plus ipilimumab for first-line treatment of advanced renal cell carcinoma (RCC), and how these mature overall survival (OS) data influence the view of nivolumab plus ipilimumab as a frontline option, alongside insights from efficacy, safety, post hoc subgroup analyses (Albiges et al, Eur Urol, 2022), and health-related quality of life (HRQOL) data (Cella et al, J Clin Oncol, 2022).

Latest Updated Articles